Radcliffe Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Radcliffe Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-308,841	Closed	-$3.12M	–	831
2022 Q4	$3.12M	Buy	308,841 +95,242	+45%	+$952K	0.1%	320
2022 Q3	$2.12M	Sell	213,599 -1	-0%	-$10	0.05%	611
2022 Q2	$2.09M	Hold	213,600	–	–	0.05%	645
2022 Q1	$2.09M	Buy	213,600 +13,600	+7%	+$132K	0.05%	625
2021 Q4	$1.94M	Hold	200,000	–	–	0.05%	601
2021 Q3	$1.95M	Hold	200,000	–	–	0.06%	492
2021 Q2	$1.94M	Buy	+200,000	New	+$1.96M	0.06%	517

Radcliffe Capital Management's EBAC Position: Q1 2023 in Review

Radcliffe Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 308,841 shares — an estimated $3.12M sold.

Radcliffe Capital Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $3.12M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Radcliffe Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Radcliffe Capital Management sold 308,841 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $3.12M.
Radcliffe Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Radcliffe Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $3.12M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.